Bruker Corporation $BRKR Shares Sold by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. trimmed its position in shares of Bruker Corporation (NASDAQ:BRKR – Free Report) by 6.2% in the third quarter, HoldingsChannel.com reports. The fund owned 2,647,424 shares of the medical research company’s stock after selling 175,754 shares during the period. Bruker accounts for 2.1% of Edmond DE Rothschild Holding S.A.’s holdings, making the stock its 8th largest position. Edmond DE Rothschild Holding S.A.’s holdings in Bruker were worth $171,421,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Pallas Capital Advisors LLC purchased a new stake in Bruker during the second quarter worth about $570,746,000. Primecap Management Co. CA acquired a new position in shares of Bruker in the second quarter valued at approximately $53,145,000. Bank of New York Mellon Corp acquired a new position in shares of Bruker in the second quarter valued at approximately $44,839,000. Old West Investment Management LLC purchased a new stake in Bruker during the 2nd quarter worth approximately $40,146,000. Finally, Alyeska Investment Group L.P. increased its stake in Bruker by 86.2% during the 2nd quarter. Alyeska Investment Group L.P. now owns 1,410,164 shares of the medical research company’s stock worth $84,864,000 after buying an additional 653,007 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Stock Performance

NASDAQ:BRKR opened at $62.10 on Friday. The firm has a market capitalization of $9.48 billion, a PE ratio of -56.45, a price-to-earnings-growth ratio of 1.84 and a beta of 1.26. The business’s fifty day moving average price is $59.93 and its 200 day moving average price is $51.25. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.84 and a quick ratio of 0.90. Bruker Corporation has a 12 month low of $32.37 and a 12 month high of $68.98.

Bruker (NASDAQ:BRKR – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.14. Bruker had a positive return on equity of 13.76% and a negative net margin of 3.82%. The business had revenue of $874.00 million for the quarter, compared to the consensus estimate of $865.16 million. During the same quarter in the prior year, the business posted $0.45 EPS. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. On average, sell-side analysts anticipate that Bruker Corporation will post 2.13 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 7th. Shareholders of record on Monday, December 21st will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 21st. Bruker’s dividend payout ratio is currently -18.18%.

Insiders Place Their Bets

In other news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the sale, the vice president owned 134,806 shares in the company, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 27.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on BRKR. Stifel Nicolaus set a $50.00 price target on shares of Bruker in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research note on Monday, August 31st. The Goldman Sachs Group raised Bruker from a “strong sell” rating to a “strong-buy” rating in a research note on Monday, September 21st. Guggenheim increased their price target on Bruker from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Finally, JPMorgan Chase & Co. cut Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 price objective for the company. in a research note on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $60.62.

Check Out Our Latest Analysis on Bruker

Bruker Profile

(Free Report)

Bruker develops and manufactures scientific instruments and analytical technologies used to study biological, chemical and physical materials. Its products support research and testing in areas including life sciences, pharmaceuticals, biotechnology, materials science, chemicals and clinical diagnostics. The company’s offerings include nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray and microscopy instruments, and infrared and Raman spectroscopy solutions.

Featured Articles

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR – Free Report).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.